Novo Nordisk has reported the theft of multiple batches of its critical injectable drug products during transit from its Bhiwandi Hub to destinations on the milk route covering Nagpur, Raipur, Cuttack, and Kolkata.
According to the company, the stolen products include rDNA origin injectables, which require strict cold-chain storage at 2–8°C. Improper handling or exposure to unsuitable conditions could compromise product quality and pose risks to patient safety. The case is currently under investigation by the police.
The affected batches include :
Ryzodeg™ FlexTouch® (Insulin degludec/Insulin Aspart, r-DNA origin) – Batch No. RT6GY96
Fiasp® Penfill® (Insulin Aspart, r-DNA origin) – Batch No. RR726A8
Fiasp® FlexTouch® (Insulin Aspart, r-DNA origin) – Batch No. RP5P640
Wegovy® FlexTouch® (Semaglutide Injection 0.5mg, r-DNA origin) – Batch No. RP5S233
Wegovy® FlexTouch® (Semaglutide Injection 0.25mg, r-DNA origin) – Batch No. RP5S232
Wegovy® FlexTouch® (Semaglutide Injection 1mg, r-DNA origin) – Batch No. RP5S210
Advisory Issued
Authorities have issued an alert and urged caution across stakeholders:
Doctors and healthcare professionals are advised to carefully prescribe these medicines and counsel patients to promptly report any adverse drug reactions (ADRs).
Patients and consumers are strongly advised to purchase only from authorized pharmacies with proper invoices and to remain alert against unauthorized sources.
Regulatory authorities including all state and UT Drug Controllers, as well as CDSCO zonal/sub-zonal offices, have been instructed to keep strict vigil on the circulation of these batches and to initiate necessary action under the Drugs & Cosmetics Act, 1940.
The Central Drugs Standard Control Organization (CDSCO) has called for heightened surveillance to prevent misuse of the stolen stock and to ensure patient safety.
